Trisalus Life Sciences, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$4.8Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
2,018clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $699K
2020 $255K
2021 $199K
2022 $702K
2023 $1.2M
2024 $443K
2025 $1.4M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Vascular & Interventional Radiology $2.5M
Diagnostic Radiology $1.1M
Surgical Oncology $761K
Nephrology (Internal Medicine) $126K
Medical Oncology $77K
Internal Medicine $72K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Alexander Kim Oxon Hill, MD Vascular & Interventional Radiology $607,119.88
Steven Katz Providence, RI Surgical Oncology $494,391.75
Dennis Griffin Englewood, CO Diagnostic Radiology $330,998.32
Riad Salem Chicago, IL Vascular & Interventional Radiology $265,484.07
Robert Lewandowski Chicago, IL Vascular & Interventional Radiology $261,196.15
David Porter Greenwood Village, CO Diagnostic Radiology $260,146.13
Richard Marshall Jr New Orleans, LA Vascular & Interventional Radiology $198,293.90
James Luethke Englewood, CO Diagnostic Radiology $195,055.63
Aravind Arepally Atlanta, GA Vascular & Interventional Radiology $154,541.06
John Hardaway Shenandoah, TX Surgical Oncology $147,169.12

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.